Events
Tuesday, a panel of experts took on stiff questions about pain/addiction therapeutics during a panel hosted by the Biotechnology Innovation Organizaion (BIO) in NYC.
At the Advances in Genome Biology and Technology general meeting, innovators from industry and academia discuss how recent advances in whole genome sequencing are propelling cancer research.
Servier and Taiho Oncology announced Tuesday that Lonsurf in combination with bevacizumab improved overall survival rates in patients with refractory metastatic colorectal cancer.
Elicio Therapeutics entered into a merger agreement as a wholly-owned subsidiary of Angion Biomedica Co. on Tuesday, becoming a Nasdaq-listed company.
The FDA approved Novo Nordisk’s Rybelsus as a first-line treatment option for adults with type 2 diabetes, signaling a shift from its previous indication as a second-line approach.
The past decade has seen an immuno-oncology revolution, but there is still work to be done. BioSpace looks at innovative research from Nectin Therapeutics, Compugen and Biond Biologics.
At JPM Wednesday, Ionis CEO Brett Monia touted nine positive late- and mid-stage readouts from 2022 and set up the company’s commercial prospects for 2023.
Stay on top of what’s happening at JPM. BioSpace is covering all the key announcements all week.
In a fireside chat at the 41st J.P. Morgan Healthcare Conference in San Francisco, CEO Rick Gonzalez said AbbVie is well-positioned for continued growth.
The drugmaker’s presentation highlights its strong revenue growth, dominant vaccine business and expanding oncology portfolio.
PRESS RELEASES